🔗 Share this article

A shadow economy for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Drug Gaining Traction Online

The experimental drug, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are encouraged to message these accounts privately for source information, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where groups with thousands of members share comparison images, administration instructions and claims of next-day British shipping. Sellers market the drug there before redirecting customers to other platforms for transactions.

Understanding Retatrutide

This medication is an experimental injectable created by US drugmaker Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Early trials suggest it could assist patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.

Healthcare Professionals Express Concerns

However, doctors and pharmacists have cautions that the sale of what is still an unlicensed medication in the UK is worrisome and could result in users administering products of unknown origin.

Some professionals said the popularity for retatrutide could be linked to the rising price of licensed slimming products such as Mounjaro.

Regulatory Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that must not be marketed or supplied for human use under the British medical regulations.

Several content creators try to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.

Service Response and Material Removal

According to the social media company, the service has taken down problematic content and banned related hashtags and search suggestions. The company stated it was dedicated to maintaining the platform secure and investing in strengthening compliance measures.

Digital Trading Operations

Research also discovered groups with up to nine thousand members marketing the experimental drug using Telegram's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately brings up groups with numerous of users, filled with images of slimming results, positive testimonials and step-by-step instructions for mixing or injecting at home.

After moments of joining one community, a seller posted WhatsApp details, where most transactions take place. The vendor provided an guidebook and promised shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. None asked about weight, medical conditions or past usage.

Product Details and Pricing

Within these communities, messages display black plastic packages with postal service stickers, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with purified liquid, or ready-to-use pens typically sold at £160 for 20mg. When questioned how long a injector should be used, sellers give contradictory responses varying between a several days to “depends on your body”.

Platform Moderation and Security Measures

A spokesperson for Telegram stated it actively moderated dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are administering substances they can’t verify. Although the research behind retatrutide is valid, these digital products may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service linked the increase in interest to current cost increases for authorized slimming medications such as Mounjaro. “With prices increasing, patients are turning to social media. But fake treatments are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.

Her staff has previously seen patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your well-being,” said the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly stated retatrutide was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they said, noting that any item “falsely representing itself as a Lilly experimental substance not yet authorized … may subject patients to possibly serious health risks”.